Business Context and Reporting Period
Supernus Pharmaceuticals, Inc. (Supernus) filed a Form 8-K on June 13, 2025, announcing the entry into a Material Definitive Agreement. On this date, Supernus, Sage Therapeutics, Inc. (Sage), and Saphire Inc. (a wholly-owned subsidiary of Supernus) executed an Agreement and Plan of Merger. The transaction involves a tender offer to acquire all outstanding shares of Sage common stock, followed by a merger where Sage will become a wholly-owned subsidiary of Supernus.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the proposed acquisition rather than Supernus's standalone operating results for a specific period.
- Offer Price: $8.50 per share in cash, plus one Contingent Value Right (CVR) per share.
- Maximum CVR Value: $3.50 per share, contingent on future sales milestones.
- Total Maximum Consideration: $12.00 per share ($8.50 cash + $3.50 CVR).
- Termination Fee: $22,376,056 payable by Sage under specific termination scenarios (e.g., accepting a superior offer or failing to recommend the transaction).
- Revenue Context: Supernus will receive collaboration revenue equal to 50% of total net revenue Biogen records for Zurzuvae in the United States.
Note: The filing does not provide Supernus's current revenue, profit, cash flow, debt, or liquidity metrics. These figures are not disclosed in this specific 8-K report.
Material Changes and Milestone Payments
The primary material change is the initiation of the acquisition process for Sage Therapeutics. The CVR structure ties future payments to the commercial performance of Zurzuvae (a treatment for Major Depressive Disorder). Milestone payments are as follows:
- $1.00 per share: If annual net sales of Zurzuvae allocable to Supernus reach at least $250 million in the U.S. by the end of 2027.
- $1.00 per share: If annual net sales reach at least $300 million in the U.S. by the end of 2028.
- $1.00 per share: If annual net sales reach $375 million in the U.S. by the end of 2030.
- $0.50 per share: Upon the first commercial sale in Japan to a third-party customer after regulatory approval by June 30, 2026.
Guidance, Outlook, and Risks
Outlook and Timeline:
- The tender offer is scheduled to commence no later than July 2, 2025.
- The offer will initially remain open for 20 business days, with potential extensions of up to 10 business days each.
- Supernus and Sage held an investor conference call on June 16, 2025, to discuss the transaction.
- Conditions to Closing: The transaction is subject to customary conditions, including the expiration of the HSR Act waiting period, the absence of a Material Adverse Effect, and the tender of more than 50% of outstanding shares.
- Superior Offer: Sage retains the right to terminate the agreement to accept a superior alternative acquisition proposal, subject to paying the termination fee.
- Regulatory Approval: The Japan milestone payment is contingent on regulatory approval by Shionogi & Co., Ltd.
The Merger Agreement includes customary "no-solicitation" provisions, though Sage may engage with third parties regarding a bona fide superior offer. Sage's board has agreed to unanimously recommend the tender offer to its stockholders.
Key Facts for Investor Verification
- Verify the exact number of outstanding Sage shares to calculate the total transaction value.
- Review the upcoming Schedule TO (Tender Offer Statement) and Schedule 14D-9 for detailed risk factors and offer terms.
- Monitor the status of the HSR Act waiting period, which is a condition for the offer's acceptance.
- Assess the commercial trajectory of Zurzuvae to evaluate the likelihood of achieving the $3.50 CVR milestones.
- Confirm the final terms of the CVR Agreement, which will be entered into at or prior to the acceptance of tendered shares.